194 related articles for article (PubMed ID: 36568640)
1. Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study.
Dong X; Wang Y; Hao J; Chen L; Sun T; Zhang W; Sun B; Zhu L; Guo Y; Zheng C
J Oncol; 2022; 2022():1090313. PubMed ID: 36568640
[TBL] [Abstract][Full Text] [Related]
2. Lipiodol combined with drug-eluting beads versus drug-eluting beads alone for transarterial chemoembolization of hepatocellular carcinoma: a multicenter study.
Ji K; Shi Y; Liang Z; Zhang C; Jing L; Xu T; Cao S; Zhou G; Cao Y; Niu J; Zhu J; Ai J; Li Z; Chen F
Acad Radiol; 2024 Jun; ():. PubMed ID: 38866689
[TBL] [Abstract][Full Text] [Related]
3. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Shi Q; Chen D; Zhou C; Liu J; Huang S; Yang C; Xiong B
Cancer Manag Res; 2020; 12():5461-5468. PubMed ID: 32753963
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of raltitrexed-eluting CalliSpheres
Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
[TBL] [Abstract][Full Text] [Related]
5. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
6. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis.
Bargellini I; Lorenzoni V; Lorenzoni G; Scalise P; Andreozzi G; Bozzi E; Giorgi L; Cervelli R; Scandiffio R; Perrone O; Meccia DV; Boccuzzi A; Daviddi F; Cicorelli A; Lunardi A; Crocetti L; Turchetti G; Cioni R
Eur Radiol; 2021 Oct; 31(10):7512-7522. PubMed ID: 33871708
[TBL] [Abstract][Full Text] [Related]
7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
8. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
9. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
[TBL] [Abstract][Full Text] [Related]
10. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
[TBL] [Abstract][Full Text] [Related]
11. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
13. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
14. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
Front Oncol; 2021; 11():793581. PubMed ID: 35127501
[TBL] [Abstract][Full Text] [Related]
15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.
Chen YC; Huang CW; Li CC; Chang TK; Su WC; Chen PJ; Yeh YS; Chang YT; Tsai HL; Shih MP; Wang JY
World J Surg Oncol; 2023 Dec; 21(1):378. PubMed ID: 38041083
[TBL] [Abstract][Full Text] [Related]
17. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma-A Propensity Score Weighted Comparison of Efficacy and Safety.
Savic LJ; Chen E; Nezami N; Murali N; Hamm CA; Wang C; Lin M; Schlachter T; Hong K; Georgiades C; Chapiro J; Laage Gaupp FM
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497329
[TBL] [Abstract][Full Text] [Related]
18. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
20. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]